BioAge Labs, Inc. (NASDAQ:BIOA) Short Interest Update

BioAge Labs, Inc. (NASDAQ:BIOA) was the target of a large growth in short interest in February. As of February 13th, there was short interest totaling 1,341,664 shares, a growth of 47.6% from the January 29th total of 909,129 shares. Based on an average daily volume of 644,382 shares, the short-interest ratio is presently 2.1 days. Approximately 4.7% of the company’s stock are short sold. Approximately 4.7% of the company’s stock are short sold. Based on an average daily volume of 644,382 shares, the short-interest ratio is presently 2.1 days.

Insider Buying and Selling at BioAge Labs

In other BioAge Labs news, insider Paul D. Rubin sold 7,433 shares of the business’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $18.75, for a total value of $139,368.75. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Kristen Fortney sold 233,107 shares of the firm’s stock in a transaction on Tuesday, January 13th. The shares were sold at an average price of $18.12, for a total value of $4,223,898.84. Following the sale, the chief executive officer directly owned 976,949 shares of the company’s stock, valued at approximately $17,702,315.88. This represents a 19.26% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 354,437 shares of company stock worth $5,813,228. Insiders own 20.82% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. CWM LLC lifted its holdings in shares of BioAge Labs by 39.9% in the fourth quarter. CWM LLC now owns 3,693 shares of the company’s stock worth $49,000 after buying an additional 1,053 shares in the last quarter. Russell Investments Group Ltd. purchased a new stake in BioAge Labs in the 3rd quarter worth approximately $27,000. China Universal Asset Management Co. Ltd. purchased a new position in shares of BioAge Labs during the 4th quarter valued at $77,000. Police & Firemen s Retirement System of New Jersey bought a new position in shares of BioAge Labs in the second quarter worth $27,000. Finally, Nisa Investment Advisors LLC raised its position in shares of BioAge Labs by 4,219.4% in the fourth quarter. Nisa Investment Advisors LLC now owns 10,237 shares of the company’s stock worth $135,000 after buying an additional 10,000 shares in the last quarter.

Analyst Ratings Changes

A number of research firms recently issued reports on BIOA. Weiss Ratings restated a “sell (d-)” rating on shares of BioAge Labs in a report on Tuesday, January 27th. Wall Street Zen raised shares of BioAge Labs from a “sell” rating to a “hold” rating in a report on Tuesday, February 3rd. Morgan Stanley set a $23.00 price objective on BioAge Labs in a report on Wednesday, February 4th. Oppenheimer started coverage on BioAge Labs in a research note on Wednesday. They issued an “outperform” rating and a $60.00 target price on the stock. Finally, Piper Sandler assumed coverage on BioAge Labs in a research note on Tuesday, January 27th. They set an “overweight” rating for the company. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $32.67.

BioAge Labs Price Performance

NASDAQ:BIOA opened at $22.27 on Friday. BioAge Labs has a 1 year low of $2.88 and a 1 year high of $24.00. The stock’s fifty day moving average price is $18.29 and its two-hundred day moving average price is $10.95. The company has a market cap of $798.38 million, a P/E ratio of -14.65 and a beta of 1.42.

BioAge Labs Company Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.